Status: Recruiting
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Participants needed: 12,000
Trial details
Age: 45-84Biological sex: AllType: ObservationalSponsor: Universal DiagnosticsUpdated: Nov 10, 2025Locations: 1
Eligibility criteria
Subjects aged 45-84 years at time of consent [+5]
Undergoing colonoscopy for investigation of CRC risk symptoms [+13]